|Articles|July 10, 2015

Special Reports

  • Gastrointestinal Cancers (Issue 5)
  • Volume 4
  • Issue 2

Surivival Benefit of Regorafenib in CORRECT and CONCUR Trials

Axel Grothey, MD, medical oncologist, Mayo Clinic, discusses the survival benefit of regorafenib in CORRECT and CONCUR trials.


Latest CME